Business Wire

Codethink Achieves Positive Functional Safety Assessment to IEC 61508 and ISO 26262 Standards for the Eclipse Trustable Software Framework

Share

Codethink announced that it has successfully achieved a positive and complete Functional Safety Assessment for the Eclipse Trustable Software Framework (TSF).

Performed by exida, a globally recognised authority in functional safety, the assessment was conducted in accordance with IEC 61508 requirements, with domain experts ensuring full alignment and compatibility with ISO 26262, the automotive industry’s functional safety standard. The evaluation represents a major milestone in Codethink’s mission to transform how the world engineers, verifies, and trusts software.

According to the assessment, “considering the process objectives of both IEC 61508 and ISO 26262, the specification of Trustable [Trustable Software Framework] and the reference implementation that maps Trustable tenets and assertions to the objectives in IEC 61508, it is determined that Trustable sets out an approach to software development which meets and in many cases exceeds the rigor and expectations established for software in IEC 61508 at SIL 3.”

The report further concludes that “organizations that attempt to implement TSF according to the reference model may proceed confidently that they will be able to measure their progress towards a future certification attempt safe in the knowledge that the requirements for a successful assessment will be met.”

“This assessment validates that trust in software, especially open source, can be both measurable and auditable,” said Paul Sherwood, Codethink’s Chairman. “Functional safety is no longer a checkbox, it’s a design principle. The Eclipse Trustable Software Framework gives organizations the means to demonstrate integrity at every stage of development.”

The Eclipse Trustable Software Framework defines six tenets, Provenance, Construction, Changes, Expectations, Results, and Confidence, each mapped to the objectives of IEC 61508 and ISO 26262. This structure enables companies to align open source and proprietary development with safety-critical rigor, ensuring traceability and reproducibility from concept to deployment.

By embedding these principles directly into everyday engineering workflows, TSF bridges the long-standing divide between compliance and innovation. It provides regulators, insurers, and developers with a shared language for evaluating and improving the trustability of complex software systems.

This Functional Safety Assessment follows a series of Codethink milestones, including the contribution of the TSF to the Eclipse Foundation, as well as the successful baseline safety assessment of CTRL OS using the TSF.

“We remain focused on the real work of engineering safety, security, and reliability, not simply collecting certificates,” added Sherwood. “At its core, this is about trust: Trust that software will behave as intended, and trust that our systems and mitigations will perform when it matters most.”

Download the TSF Functional Safety Assessment report at https://www.codethink.co.uk/trustable-software-framework.html.

About Codethink

Codethink is a world-class provider of critical, high-performance software projects and solutions for international-scale companies in a range of industries including Automotive, Finance, Medical, and IoT. Headquartered in Manchester, UK, Codethink has pioneered software industry thinking around concepts of trustable software, working to improve the quality of software engineering.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251030029293/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers30.10.2025 14:00:00 CET | Press release

An Alliance to Combat Resistance: Debiopharm and NetTargets will collaborate to develop next-generation, dual-payload Antibody-Drug Conjugates (ADCs) designed to overcome acquired resistance mechanisms in difficult-to-treat cancers. AI-Powered Precision: The collaboration combines NetTargets' proprietary AI discovery platform—to identify synergistic drug pairings—with Debiopharm’s MLINK Duo technology for coordinated delivery of two distinct warheads on a single ADC. Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs). This allianc

Bending Spoons Raises $710M for Continued Investment and Growth30.10.2025 14:00:00 CET | Press release

Bending Spoons, one of Europe’s leading technology companies, today announced it has raised $710 million in equity at a pre-money valuation of $11 billion. The round was led by accounts advised by T. Rowe Price Investment Management, Inc., with participation from Baillie Gifford, Cox Enterprises, Durable Capital Partners, Fidelity Management & Research Company, Foxhaven Asset Management, and Radcliff, among others. Goldman Sachs International acted as sole placement agent and Clifford Chance served as legal advisor to the transaction. Notarial advisory services were provided by ZNR Notai. “This moment is a validation of a decade’s worth of work and it serves as an important recognition of what we’ve accomplished at Bending Spoons so far. We remain early in our journey and have ambitious plans for continued investment and growth,” shares Luca Ferrari, co-founder and CEO of Bending Spoons. “We’re proud to bring on some of the world’s finest investors who believe in our approach to value

Owlet® Strengthens Market Leadership as Dream Sight™ Becomes the First Baby Monitor Awarded the SGS Cybersecurity Mark30.10.2025 13:45:00 CET | Press release

Earning the first-ever SGS Cybersecurity Mark in the baby monitor category, Owlet reinforces its leadership in safety, security, privacy, and innovation. Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced that its newest video monitoring device, Dream Sight, is the first and only baby monitor to earn an SGS Cybersecurity Mark, a global certification that recognizes the highest standards in international cybersecurity and privacy. Dream Sight was tested by Brightsight, an SGS company and global leader in cybersecurity evaluations. For parents, this independent recognition provides extra reassurance that Owlet delivers trusted digital solutions backed by strong encryption, secure data management, and advanced privacy safeguards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106669800/en/ Owlet's Dream Sight is the first and only baby monitor to earn an SGS Cybersecu

Crown Bioscience Achieves Second CLIA Certification of 2025 at Suzhou Laboratory30.10.2025 13:30:00 CET | Press release

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced that its Suzhou, China laboratory has received Clinical Laboratory Improvement Amendments (CLIA) certification. This achievement marks the company’s second CLIA certification in 2025, following its San Diego facility earlier this year, underscoring Crown Bioscience’s continued commitment to expanding its global network of compliant, clinical-grade laboratories. Regulated by the Centers for Medicare and Medicaid Services (CMS), CLIA certification sets the highest federal standards for laboratory accuracy, reliability, and quality. The designation affirms that Crown Bioscience’s Suzhou laboratory meets all required compliance benchmarks, providing clients with greater confidence in the biomarker data that supports their clinical development and regulatory submissions. ‘’Earning a second CLIA certification within

SLB OneSubsea Secures EPC Contracts from PTTEP for Two Deepwater Projects Offshore Malaysia30.10.2025 13:30:00 CET | Press release

Integrated subsea production systems will help unlock important oil and gas reserves Global energy technology company SLB (NYSE: SLB) announced today the award of two sizeable engineering, procurement, and construction (EPC) contracts by PTT Exploration and Production Public Company Limited (PTTEP) to its OneSubsea™ joint venture. The contracts build on a 20-year collaboration between the two companies and cover the expansion of two fields offshore Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030090404/en/ As part of the EPC contracts, SLB OneSubsea will deliver comprehensive subsea production systems (SPS) for the Alum, Bemban, and Permai deepwater gas fields located in Block H and the Kikeh field, Malaysia’s first deepwater oil project. As part of the EPC contracts, SLB OneSubsea will deliver comprehensive subsea production systems (SPS) for the Alum, Bemban, and Permai deepwater gas fields located in Block

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye